Heterogeneity in the Effect of Early Goal-Directed Therapy for Septic Shock: A New Perspective

Heterogeneity in the Effect of Early Goal-Directed Therapy for Septic Shock: A New Perspective

A recent secondary analysis of the ARISE and ProCESS trials offers valuable insights into the varying effectiveness of Early Goal-Directed Therapy (EGDT) in patients with septic shock. Despite previous randomized controlled trials showing mixed results, this study highlights significant heterogeneity in treatment responses, suggesting that EGDT may benefit some patients while potentially causing harm to others.
Understanding Rift Valley Fever Virus Encephalitis: Viral and Host Determinants of Pathogenesis

Understanding Rift Valley Fever Virus Encephalitis: Viral and Host Determinants of Pathogenesis

Rift Valley fever virus (RVFV), a mosquito-borne virus endemic to Africa and the Middle East, poses significant health risks due to its potential to cause severe encephalitis. In this review, Lindsay R. Wilson and Anita K. McElroy from the University of Pittsburgh School of Medicine shed light on the viral and host factors influencing RVFV encephalitis. They explore the role of host genetics, immune responses, and the mechanisms of central nervous system invasion.
Exploring New Avenues for Antifungal Therapies: The Role of SUMO-Targeted Ubiquitin Ligases in Candida glabrata

Exploring New Avenues for Antifungal Therapies: The Role of SUMO-Targeted Ubiquitin Ligases in Candida glabrata

A recent study published in PLOS Pathogens delves into the intricate mechanisms of protein homeostasis in Candida glabrata, an opportunistic human pathogen known for its resistance to standard antifungal treatments. The research, led by Dipika Gupta, Renu Shukla, and Krishnaveni Mishra from the University of Hyderabad, highlights the critical role of SUMO-targeted ubiquitin ligases (STUbLs) in regulating protein stability within the pathogen.
Comparative Effectiveness of Baricitinib vs. Tocilizumab in Hospitalized COVID-19 Patients: Key Insights from a National Cohort Study

Comparative Effectiveness of Baricitinib vs. Tocilizumab in Hospitalized COVID-19 Patients: Key Insights from a National Cohort Study

A recent study published in Critical Care Medicine explores the comparative effectiveness of baricitinib and tocilizumab in hospitalized COVID-19 patients. Utilizing data from the National COVID Cohort Collaborative (N3C)—the largest electronic health records database on COVID-19 in the U.S.—this multicenter, retrospective cohort study analyzed outcomes from over 10,000 patients across 75 hospitals.
Rectal Temperature: A Game-Changer in Diagnosing Intrapartum Infections

Rectal Temperature: A Game-Changer in Diagnosing Intrapartum Infections

A recent letter published in the American Journal of Obstetrics & Gynecology highlights the critical role of rectal temperature measurement in improving the diagnosis of intrapartum infections. While oral temperature measurements are commonly used, they often underestimate core body temperature, potentially delaying the diagnosis of conditions like chorioamnionitis.
A New Year, A New Chapter in Hematology

A New Year, A New Chapter in Hematology

As we step into 2025, we reflect on the incredible progress made in hematology and set our sights on the breakthroughs to come. This heartfelt message celebrates the dedication of our doctors, researchers, and patients who inspire hope and innovation every day. Let’s work hand in hand to bring new solutions, brighter outcomes, and life-changing treatments to patients worldwide. Together, we can push the boundaries of medicine and create miracles in hematology. Watch this inspiring New Year message as we welcome a year of health, happiness, and progress. Let’s embrace 2025 with hope and determination!
93 Research Achievements of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences Were Showcased at the 66th ASH

93 Research Achievements of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences Were Showcased at the 66th ASH

The 66th Annual Meeting of the American Society of Hematology (ASH), the largest global academic event in the field of hematology, took place from December 7 to 10, 2024, in San Diego, USA. The event brought  together leading researchers and clinicians from around the world to discuss cutting-edge advancements in hematology, innovative therapies, and ongoing clinical trials.Following rigorous peer review, 10 high-quality abstracts from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences were selected for oral presentations, and an additional 83 abstracts were featured in poster sessions.
JITC丨Combination of Autologous Transplantation and CAR-T Cells Enhances Outcomes in Refractory Large B-Cell Lymphoma: Findings from the Team of Professor Dehui Zou and Professor WentingZheng

JITC丨Combination of Autologous Transplantation and CAR-T Cells Enhances Outcomes in Refractory Large B-Cell Lymphoma: Findings from the Team of Professor Dehui Zou and Professor WentingZheng

Chimeric antigen receptor T-cell (CAR-T) therapy is one of the most promising salvage treatments for relapsed/refractory large B-cell lymphoma (r/r LBCL), offering durable remission for about one-third of patients. However, the remaining two-thirds either fail to respond to CAR-T therapy or experience relapse, resulting in poor survival outcomes. This underscores the urgent need to explore methods to enhance the efficacy of CAR-T therapy.